Dermata Therapeutics (NASDAQ:DRMA) Issues Quarterly Earnings Results

Dermata Therapeutics (NASDAQ:DRMA) announced its quarterly earnings data on Tuesday. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.19), FiscalAI reports.

Dermata Therapeutics Price Performance

Dermata Therapeutics stock traded down $0.05 during trading hours on Thursday, reaching $1.33. The stock had a trading volume of 569,662 shares, compared to its average volume of 1,133,056. The company has a fifty day simple moving average of $1.25 and a 200-day simple moving average of $1.35. Dermata Therapeutics has a 52 week low of $0.95 and a 52 week high of $6.54. The stock has a market cap of $5.33 million, a PE ratio of -0.30 and a beta of 0.66.

Institutional Trading of Dermata Therapeutics

A hedge fund recently bought a new position in Dermata Therapeutics stock. Clear Street Group Inc. bought a new stake in Dermata Therapeutics, Inc. (NASDAQ:DRMA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned 0.60% of Dermata Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 8.67% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Dermata Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Dermata Therapeutics has a consensus rating of “Hold” and a consensus price target of $10.00.

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.